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Abstract: Collagen fibres degradation is a complex process involving a variety of enzymes. Fibril-
lar collagens, namely type I, II, and III, are the most widely spread collagens in human body, e.g., 
they are responsible for tissue fibrillar structure and skin elasticity. Nevertheless, the hyperactivity 
of fibrotic process and collagen accumulation results with joints, bone, heart, lungs, kidneys or liv-
er fibroses. Per contra, dysfunctional collagen turnover and its increased degradation leads to 
wound healing disruption, skin photoaging, and loss of firmness and elasticity. In this review we 
described the main enzymes participating in collagen degradation pathway, paying particular at-
tention to enzymes degrading fibrillar collagen. Therefore, collagenases (MMP-1, -8, and -13), elas-
tases, and cathepsins, together with their peptide and peptidomimetic inhibitors, are reviewed. 
This information, related to the design and synthesis of new inhibitors based on peptide structure, 
can be relevant for future research in the fields of chemistry, biology, medicine, and cosmeceuti-
cals. 
Keywords: peptides; peptidomimetics; collagen; enzyme inhibitors; cosmeceuticals 
 
1. Introduction 
Collagen is one of the most essential proteins in the human body and a major com-
ponent of the extracellular matrix (ECM) [1]. There are 28 classified collagen types, of 
which collagen type I forms around 85%, with up to 15% formed by type III [2,3]. Type I 
composes mainly the tissue fibrillar structure, while type III functions as the linchpin of 
type I fibres and supports skin elasticity. Collagen, in general, represents approximately 
one-third of all human body proteins, being the most abundant protein-like body com-
ponent [4]. On the basis of molecular structure, collagen is classified into three morpho-
logical forms, namely fibrillar, non-fibrillar, and network-forming collagens [5].  
Three polypeptide collagen molecules spontaneously form a helical structure, so-
called tropocollagen. A single chain (α chain) has usually the length of about 1000 resi-
dues [6]. Tropocollagen is stabilized by covalent bonds and hydrogen interactions be-
tween hydroxyproline (HyP) and hydroxylysine (HyK) [2]. It was observed that tropo-
collagen superhelix is visibly more constrained, with the rise per residue value of 0.29 
nm comparing to 0.36 nm for common proteins [7]. This feature makes it exceptionally 
resistant to the widespread proteolytic digestion, making collagen susceptible only to a 
few enzymes [8]. Remarkable regularity of repeated amino acid triad, Gly-X-Y (where 
X—proline, Pro; Y—hydroxyproline, HyP), provides a variety of beneficial properties—
for instance, stability and resistance to distortion. Glycine replacement by larger and 
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more branched residues provokes inaccurate folding and decreases helix resistance to 
external conditions, i.e., temperature [7]. 
The essential role played by collagen in the human body has a relevant influence on 
many physiological, as well as pathological states. Collagen turnover is the complex and 
interconnected process of collagen biosynthesis and degradation. In physiological states, 
the degradative pathway acts as a regulator of collagen deposition, thus preventing var-
ious fibrotic disorders. Moreover, a proper intracellular collagen degradation prevents 
the secretion of defective sequences [9]. Accordingly, the control of collagen homeostasis 
is one of the major factors in bleeding syndromes therapies [10], while hyperactivity of 
fibrotic process and collagen accumulation results with joints, bone, heart, lungs, kid-
neys or liver fibroses [4,11,12]. Per contra, dysfunctional collagen turnover and its in-
creased degradation lead to wound healing disruption, skin photoaging, and loss of skin 
firmness and elasticity [13]. The latter aspects are particularly relevant in the field of aes-
thetic medicine and cosmetics, to which we will pay special attention. 
In this review we will briefly describe the collagen turnover process in relevant cells 
and tissues, indicating the main degradation pathways in particular and underlining the 
key enzymes involved in these mechanisms. We will review peptide-based inhibitors of 
collagenases, elastase, and cathepsin, mentioning also some relevant non-peptide com-
pounds. The final aim is to give a valuable starting point for future research, providing 
chemical and biological basis for the design and the development of new peptide-based 
inhibitors, potentially applicable as cosmeceuticals. 
2. Collagen Turnover in Cells 
In this section, we briefly describe the collagen turnover process in relevant cells, in 
order to clarify its biosynthesis and degradation pathways. This complex process has 
been discussed in details in the following reviews: Rodriguez-Feo et al. [14], Gelse et al. 
[15], Smith and Rennie [4], Sprangers and Everts [12], together with the review by Van-
nella and Wynn, depicting the wound healing process and tissue remodelling [16]. 
Each fibrillar-type collagen is synthesised in fibroblasts in the form of procollagen, 
consisting of two N- and C-terminal propeptide domains [12,15]. There is a spectrum of 
already known collagen synthesis stimulators, such as Transforming Growth Factor beta 
(TGF-β), Endothelin-1 (ET-1), Angiotensin-II (Ang II), Platelet-Derived Growth Factor B 
(PDGF-BB), Interleukin-1 (IL-1), Aldosterone, Interferon g (IFN-g), Basic Fibroblast 
Growth Factor (bFGF) and Nitric Oxide (NO) [14]. As indicated previously, proline resi-
dues play a pivotal role in the collagen structure formation. At this point, Pro undergoes 
the hydroxylation by prolyl-3- and -4-hydroxylases, together with lysyl-hydroxylase act-
ing on Lys [1]. Then, fibrillar procollagens are secreted into the extracellular space. Af-
terwards, terminal noncollagenous fragments are removed via enzymatic cascade, thus 
enabling the spontaneous formation of fibrils. This process, called fibrillogenesis, is reg-
ulated by collagen type V and this assembling is favoured by covalent cross-linking be-
tween lysine side chains [1,12]. 
As far as degradation is concerned, the tenor of collagen disruption is strictly con-
nected to its type. Mainly, there are two recognized categories of these pathways: extra-
cellular and intracellular. Extracellular degradation includes the cleavage of mature col-
lagen, while the intracellular mechanism degrades the procollagen chains, before their 
assembling into procollagen molecules [17]. These processes prevent the formation of 
defective collagen and its incorporation into the extracellular matrix. 
The extracellular pathway is due to secreted proteolytic enzymes, capable to digest 
collagen fibres. Various enzyme classes participate in this process, i.e., matrix metallo-
proteases (MMPs), serine proteases, active at neutral pH, as well as cysteine, aspartate, 
and threonine proteases, requiring mainly acidic environment [18]. MMPs target a broad 
range of proteins, depending on the enzyme type. For example, stromelysins (MMP-3 
and -10) act preferentially on proteoglycans, fibronectin, and laminin [18]. Other MMPs, 
such as gelatinases, cleaves already denaturated collagen only. ECM modulation is af-
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fected also by the so-called A Disintegrin and Metalloproteinase (ADAM) and ADAM 
with Thrombospondin Motifs (ADAMTS) family [18,19]. The extracellular degradation 
process and the ECM dynamics, have been reviewed by Lu et al. in 2011 [18]. 
The intracellular mechanism follows the internalization of collagen fragments, pre-
viously partially degraded in the ECM [12]. The kinetics of this process was found to be 
very rapid [20,21]. Time and percentage of degradation depends on the tissue type, re-
vealing significant differences between, e.g., skin and heart. Two intracellular localiza-
tions of collagen degradation have been proposed: one within the lysosome and the sec-
ond within the cisternae (in the endoplasmic reticulum or Golgi apparatus). 
In this review, we will put a particular attention on the extracellular breakdown 
pathway, describing the most substantial enzymes involved in this process. Table 1 pre-
sents a list of enzymes participating in the degradation, with reference to the relevant 
collagen class. Figure 1 illustrates the influence of various MMPs on extracellular colla-
gen breakdown. Other factors indirectly stimulating collagen disruption are the follow-
ing [13]: (1) ultraviolet radiation, inducing MMPs and enhancing their proteolytic action; 
(2) age, due to the overactive secretion of proteases observed in elder skin, together with 
incorrect (or diminished) fibroblasts activity [2]; (3) sex, in view of an inhibitory effect of 
oestrogen on collagen synthesis [22]. Two interesting papers, describing the influence of 
menstrual cycle on collagen synthesis, were published in 2006 and 2007. These investiga-
tions did not show any significant change between luteal or follicular phases. However, 
some differences between male and female collagen synthesis and remodelling were ob-
served [23–25]. 
 
Figure 1. Collagen degradation pathway involving various MMPs [26]. 
Table 1. Major enzymes involved in the extracellular degradation pathway of collagen [8,12,14,27–41]. 
Enzyme 
Family 





Type of Preferentially De-
graded Fibrillar Collagen 
Type 1  





I, II, III, VII, VIII, 
X 
I and III 
Pro-neutral amino acid- -Gly-Pro Collagenase-2 MMP-8 
I–III, V, VII, VIII, 
X 
I 
Collagenase-3 MMP-13 II, III II, III 
Gelatinase A MMP-2 IV–VI, X n.a.  Pro-Gln-Gly- -Ile/Leu-Ala-Gly-
Gln Gelatinase B MMP-9 IV, V, VII, X, XIV n.a. 
Stromelysin-1 MMP-3 III 
III (indirectly; by the MMP-1 
activation) 
Ser- -Met 
Stromelysin-2 MMP-10 III–V III (indirectly; by the MMP-1 
activation) 




Metalloelastase MMP-12 I, IV n.a. Pro-X-X- -Leu 
Matrilysin-2 MMP-26 IV n.a. Ser- -Leu 
MT-MMP-12 MMP-14 I, II, III n.a. Ser- -Leu 
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MT-MMP-3 MMP-16 III n.a. n.a. 
Serine pro-
teases 
Elastase - I, III 
I (independently and enhanc-
ing MMPs activity) X- -Gly/Ala/Ser 
Trypsin-2 - I, II, III 
I (independently and enhanc-
ing MMPs activity) Lys/Arg- -X 
Cysteine 
proteases 
Cathepsin K CatK I, II I, II n.a. 
Cathepsin B CatB II n.a. n.a. (carboxypeptidase) 
Cathepsin L CatL I, II I Arg- -X 
Cathepsin S CatS I I n.a. 
1 n.a.: no data available. 2 MT-MMP: membrane-bound MMP. 3 : cleaved bond.. 
In this review we will focus on enzymes degrading mainly fibrillar collagen, lead-
ing to loss of skin elasticity and skin aging in general, due to their cosmeceutical interest, 
i.e., collagenases (MMP-1, 8, and 13), elastase, and cathepsins, together with their inhibi-
tors. It must be highlighted that there are two pathways of enzyme activity control—
direct (inhibition) and indirect (up or downregulation of enzymes expression) [42]. The 
following paper will consider only inhibitors directly affecting enzymes activity. 
2.1. Methods of Collagen Turnover Measurements 
As stated above, there are two interrelated pathways, contributing to collagen deg-
radation in cells: intracellular (based on lysosomal digestion) and extracellular (initially 
engaging collagenases and later on also other proteases) (Scheme 1) [4]. Due to their cor-
related activity, cellular collagen turnover measurement, including both biosynthesis 
and degradation, became a challenge. Nevertheless, there are a few methods directly 
and indirectly evaluating this factor. These discussed in our review are summarized in 
Scheme 2. 
 
Scheme 1. Collagen degradation pathways in cells. The focus of this review, enzymes participat-
ing in extracellular degradation, was highlighted in blue. 
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Scheme 2. Methods of collagen turnover measurements discussed in this review. All abbreviations 
are explained in the text above. 
2.1.1. Indirect Methods 
Collagen synthesis can be followed by the rate of appearance of specific peptides, 
deriving from procollagen: (1) PICP, C-terminal pro-peptide from collagen type I; (2) 
PINP, N-terminal pro-peptide from collagen type I; (3) Pro-C3, internal epitope in the N-
terminal pro-peptide from collagen type I; (4) P4NP7S, internal epitope in type IV colla-
gen 7S domain [4,25]. 
Degradation process can be monitored by the measurement of collagen breakdown 
markers, such as: (1) NTX and CTX, crosslinked telopeptides of type I collagen; (2) (de-
oxy)pyridinoline, pyridinium crosslinkers of type I collagen; (3) C1M, neo-epitope of 
MMP-2,9,13- mediated collagen type I degradation; (4) C3M, neo-epitope of MMP-9- 
mediated collagen type III degradation; (5) C4M, neo-epitope of MMP-2, -9, -12-
mediated collagen type IV (α1 chain) degradation [4,25]. In order to estimate collagen 
degradation products, Nielsen et al. measured the CTX-II, CTX-I, and hydroxyproline 
content in protein extract from joints [43]. Therefore, they indicated “an assessment of 
collagen degradation epitopes as a quantitative measure of cartilage damage”. 
Veidal et al. in 2011 described the applicability of ELISA assay in measuring a deg-
radation fragment specific to the type IV collagen, namely GTPSVDHGFL [44]. This ne-
oepitope is generated during MMP-induced degradation of collagen and was associated 
with liver fibrosis in animal models. 
Smith and Rennie, who listed in their review several of the above-mentioned meth-
ods, put attention on the applicability of indirect measurements [4], underlining that us-
ing these methods also some procollagen can be measured. Therefore, they are semi-
qualitative and cannot define a precise content of mature collagen in a probe.  
2.1.2. Direct Methods 
One collagen monomer contains approximately 13% of hydroxyproline residues. 
Starting from this observation, Hyp excretion in urine has been used as a collagen deg-
radation indicator. In 2005, McAnulty proposed the application of radiolabelled Hyp 
and Pro for in vitro and in vivo determination of collagen synthesis and degradation 
[45]. Moreover, the activity of prolyl-4-hydroxylase can be evaluated as an index of col-
lagen synthesis. This enzyme catalyses the proline hydroxylation, one of the initial steps 
in collagen post-translational processing [46]. The reaction takes place exclusively dur-
ing the collagen biosynthesis, therefore can be employed for the above-mentioned pur-
pose. Gorres and Raines in 2010 described for the first time a relatively simple and direct 
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assay for prolyl-4-hydroxylase, based on a detection of the Pro-containing substrate 
turnover [47].  
2.1.3. Others 
Widely described methods of collagen turnover monitoring include the use of radi-
olabelled atoms, e.g., Pro with 3H, 14C; exposure to 18O2 during the Pro hydroxylation; 
heavy water D2O administration (followed by deuterium incorporation into Ala and 
Pro). 
In 2018, Cipriani et al. described a quantitative detection of soluble collagen by 
western blot technique, similar to the protocol previously published by Poobalarahi et 
al. [27,48]. Briefly, fibroblast cell cultures were treated with trypsin in order to analyse 
the intracellular forms of collagen. The presence and intensity of bands corresponding to 
procollagen were then observed in cell lysates. 
3. Inhibitors of Collagen-Degrading Enzymes 
Fibrillar collagen is responsible for skin elasticity, firmness, and overall wellness 
and good appearance. In the field of cosmeceuticals, being on the border between tradi-
tional cosmetics and drug-like products, the claimed effect of a given cosmetic product 
should be connected with proven efficacy and activity of its active ingredient(s) [49]. 
Therefore, collagen degradation inhibitors and collagen biosynthesis enhancers are high-
ly requested and broadly investigated in the recent years. Among other classes of active 
ingredients, peptides play an important role in these fields, due to their high specificity, 
low toxicity, relatively easy synthesis, and applicability as carriers for other molecules 
[50]. However, peptides in some cases get degraded very quickly on the skin surface, or 
are not able to penetrate sufficiently into the skin layers [51]. In the aim to enhance pep-
tides stability and efficacy as bioactive ingredients, the use of peptidomimetics is in-
creasingly considered as a viable alternative to unmodified peptides. 
In general, two mechanisms of inhibition can be identified: covalent and non-
covalent binding pathways [52] (Figure 2). The covalent mechanism is based on specific 
binding to the target protein, with formation of a permanent complex with the enzyme. 
On the other hand, non-covalent inhibition assumes the semi-permanent interaction be-
tween enzyme and inhibitor, through cyclic binding, unbinding, and rebinding [53]. 
Comparing both these pathways, covalent inhibition is advantageous over the non-
covalent one. The presence of the inhibitor warhead allows the formation of particular 
interactions that leads to the development of highly specific inhibitors. Cysteine, serine, 
threonine or lysine residues participate in covalent bonds formation due to their nucleo-
philic character; hydroxyl, epoxy or carbonyl moiety in the ligand structure are usually 
responsible for the arrangement of these covalent adducts [54]. 
 
Figure 2. Illustration of two binding pathways in major inhibition mechanisms: covalent (left) and non-covalent (right) 
[53]. 
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3.1. Collagenases 
MMPs inhibitors (so-called MMPIs) have been investigated for many years, with 
the first publications from 1980. The first synthetically obtained inhibitors were charac-
terized by functional groups able to coordinate a zinc(II) ion in MMPs active site [55]. 
Relatedly, four classes of zinc MMPIs can be designated: (1) hydroxamates (CONH-O−); 
(2) carboxylates (COO−); (3) thiolates (S−); and (4) phosphinyls (PO2−) [56]. Recently, some 
commercially developed MMPIs were submitted to clinical trials, such as batimastat, 
marimastat, and others [55]. These two were then approved as drugs [57]. Despite many 
efforts in this field, selective inhibitors of specific MMPs have not been found yet. This is 
probably due to the complicated mechanism of MMPs proteolytic activity, and mutual 
interactions of many factors, leading together to the inhibition process [56]. This mecha-
nism has been studied for years, among others by Moroder and his group, which report-
ed their results in 2000 [58]. They examined the substrate specificity and preferences of 
collagenases and gelatinases, using synthetic peptides derived from collagen. It was 
clearly indicated that the inhibitory activity of both classes has different basis, but since 
the activity of all MMPs is zinc-dependent, compounds containing chelating groups are 
generally good, but weakly selective MMPIs. More detailed structural data and widely 
described catalytic activity of metalloproteases, are described in two papers by Bode and 
Maskos [59,60]. 
Studies focused on structure-activity relationship (SAR) of MMP-13 inhibitors were 
described by Roush et al., providing relevant indications for further developments 
[61,62]. In addition, both papers include the evaluation of amino acids derivatives, 
which will be further described in Section 3.1.4. 
3.1.1. Peptide Hydroxamates 
To the best of our knowledge, the very first paper describing the hydroxamate 
group (CONH-O−) as an efficient inhibitor of collagenases was published in 1986 by 
Moore and Spilburg [63]. They studied the influence on skin fibroblasts collagenases ac-
tivity of various peptide sequences, with diverse C-terminal groups (amide, carboxylate, 
aldehyde, and hydroxamate). Comparing the percentage of inhibition among amastatin, 
captopril, phosphoramidon, and zincov (standard metalloproteases inhibitors; structures 
are reported in Table 2) in 0.5 mM concentration, it was proven that only zincov was 
able to decrease the collagenases activity. Afterwards, a few sequences of hydroxamic 
acid derivatives were synthesised, in order to evaluate the influence of their length on 
inhibition efficacy. The lowest IC50 value was reported for Z-Pro-Leu-Gly-NHOH (0.04 
mM), while shortening the sequence yielded less-active inhibitors, achieving IC50 = 40 
mM for acetohydroxamic acid. It was deduced that collagenases distinguished the se-
quence including Pro due to its similarity to the cleavage site in native collagen, recog-
nized by the enzyme. Finally, to determine the role of hydroxamate in the inhibition 
mechanism, Z-Pro-Leu-Gly-X derivatives were investigated (where X indicated hydrox-
amate, carboxylate, aldehyde, and amide modification on C-terminus). The results ob-
tained for the peptide sequence with unmodified glycine residue showed the im-
portance of this sequence in the inhibition mechanism. The C-terminally merged hy-
droxamate led to satisfactory results (CM = 5.3 mM and 15% of inhibition for carboxylate; 
CM = 0.115 mM and 70% of inhibition for hydroxamate derivative). 
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Table 2. Selectivity of human collagenases inhibition, among available inhibitors of metalloproteases (by Moore and 
Spilburg) [63]. 


























In 1992, Grobelny et al. confirmed the applicability of peptide hydroxamic acids as 
collagenase inhibitors [64]. HONHCOCH2CH(i-Bu)CO-Trp-NHMe sequence isomers 
(L,L-dipeptide 6A (R,S) and D,L-dipeptide 6B (S,S)) were designed and synthesised to 
evaluate the efficacy against human skin fibroblast collagenase, thermolysin and Pseu-
domonas aeruginosa elastase. the structural difference between 6A and 6B consists in the 
CH2CH(i-Bu)CO α-carbon configuration, thus 6A is in the L-, and 6B in the D-
configuration. Surprisingly, these diastereomers distinguished very evidently the dis-
crepancy between inhibitory preferences among human (collagenase) and bacterial 
(thermolysin and elastase) enzymes. It was confirmed that the 6A inhibits collagenase 
with Ki = 0.4 nM; in the case of 6B, this value was of 200 nM. On the contrary, bacterial 
enzymes were inhibited with comparable potency by both 6A (Ki = 20 nM for each pro-
tein) and 6B (Ki = 7 nM and 2 nM for thermolysin and elastase, respectively). To confirm 
the role of hydroxamate group in the inhibitory mechanism, similarly to the previous 
paper, hydroxamic acid moiety was replaced with carboxylate and hydrazide. The Ki 
values for all of the investigated enzymes increased from the nM to μM–mM range. Al-
together, the configurational difference between 6A and 6B, both with hydroxamate 
moiety, enabled to distinguish the preferential interactions between human and bacterial 
enzymes. 
Another good example of hydroxamates as collagenases inhibitors was presented in 
1995 by Grams et al. [65]. They described X-ray structures of complexes between two 
peptide sequences and collagenase. This research was a follow-up of their previous 
work, in which the X-ray structure of collagenase with Pro-Leu-Gly-NHOH was exam-
ined [66]. Their observations led to the synthesis and evaluation of thiol inhibitor 
HSCH2CH(CH2Ph)CO-L-Ala-Gly-NH2 and hydroxamate inhibitor HON-
COCH(iBu)CO-L-Ala-Gly-NH2. Both functional groups bind to the catalytic zinc ion, 
however the hydroxamate inhibitor binds differently from the geometrical preferences 
revealed by the substrate. The calculated Ki values are: 19 μM for Pro-Leu-Gly-NHOH; 
1.2 μM for thiol-modified sequence; 33 μM for hydroxamate peptidomimetic. 
Good examples of widely studied hydroxamates, batimastat (BB-94) and marimas-
tat (BB-2516) (Figure 3), have to be mentioned in this section. Both molecules were ap-
proved as drugs after extended clinical trials, with relevant indications mostly in cancer 
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therapies. Rasmussen et al. have published a very interesting review comparing the two 
substances and summarizing clinical data [67]. 
 
Figure 3. Chemical structures of: (a) batimastat; (b) marimastat. 
Batimastat binds covalently to Zn(II) ion in the MMPs active site. It exhibits a satis-
factory influence on various MMPs, e.g., MMP-1, 3, 2, 9, and 7 (with IC50 values equal to 
3, 50, 4, 4 and 6 nM, respectively). Mimicking the substrate of metalloproteases, acts as 
competitive and reversible inhibitor. For all advantages of batimastat, it has one weak-
ness significantly diminishing its applicability—due to its poor solubility in water, has a 
very-low bioavailability after oral administration. On the contrary, marimastat can be 
administered orally with adequate results. It binds both to the zinc(II) ion and the bind-
ing site of the enzyme. Marimastat is almost as potent as batimastat, revealing reduced 
activity only against MMP-3 (IC50 values of 5, 6, 230, 16 and 3 nM against MMP-1, 2, 3, 7, 
and 9, respectively). New MMP-13 inhibitors based on hydroxamates were developed 
by Gooljarsingh et al. in 2007 [68]. Pyrimidine dicarboxamide, hydroxamate mimic, and 
acetohydroxamate were evaluated in the context of MMP-13 inhibition, resulting with 
nanomolar IC50 values for pyrimidine dicarboxamide and hydroxamate mimic, and mil-
limolar values for the less potent acetohydroxamate. 
In conclusion, hydroxamate-modified peptide inhibitors have been known for 
years, but they have been less studied in the last two decades. However, they are un-
doubtedly a group of compounds which played a pioneering role in collagenases inhibi-
tors studies and that, in our opinion, could still offer pertinent starting points for the de-
velopment of active ingredients relevant to the cosmeceutical sector. 
3.1.2. Phosphinic acid Derivatives 
Shortly after the discovery of hydroxamate peptides acting as collagenases inhibi-
tors, several compounds bearing the phosphinic acid moiety have been reported. In 1994 
Yiotakis published two papers describing linear and cyclic peptides containing phos-
phinic group (PO2−), relevant for bacterial collagenases inhibition [69,70]. Substrate ana-
logues of Corynebacterium rathayii collagenase were synthesised, replacing the scissile 
peptide bond by phosphinic moiety. Tetrapeptide Z-Phe-ψ(PO2CH2)-Gly-Pro-Nle (Fig-
ure 4) exhibited the collagenase inhibition with Ki value of 8 nM. Then, the influence of 
chain elongation was investigated. It was proven that the heptapeptide Z-Phe-Gly-Pro-
Phe-ψ(PO2CH2)-Gly-Pro-Nle-OMe is an even more effective inhibitor than his shorter 
analogue (Ki = 0.6 nM). Further modifications of the tetrapeptide, including CH2 re-
placement by NH group, demonstrated insignificant decrease of Ki value from 8 nM to 6 
nM. 
Cyclic analogues of above-mentioned sequences were studied in tandem [70]. Gen-
erally speaking, the importance of conformationally constrained peptides was under-
pinned and investigated for various applications, mainly for drug-design purposes [71–
75]. The design of new cyclic collagenase inhibitors was based on the following rules: (1) 
at least four interacting residues should be present; (2) there should be a bulky, hydro-
phobic group present in the P1 position; (3) it is required to incorporate glycine and pro-
line in P1’ and P2’ positions, respectively; (4) P3’ position should be occupied by either lin-
ear, basic or apolar side chain residue (lysine or aminocaproic acid, Ahx). Cy-
clo[Gly-Pro-Phe-ψ(PO2CH2)-Gly-Pro-Ahx] together with cy-
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clo[βAla-Pro-Phe-ψ(PO2CH2)-Gly-Pro-Ahx] were found to be relatively efficient, but not 
excellent inhibitors of this bacterial collagenase (Ki = 120 nM and 90 nM, respectively), 
comparing to the linear analogue Z-Phe-ψ(PO2CH2)-Gly-Pro-Nle (Ki = 8 nM). The role of 
configuration L and D was studied additionally, putting in a clear evidence that L ana-
logues are favourable. Therefore, it can be summarized that, linear peptides in L con-
formation, fulfilling the above-mentioned requirements, are better candidates for colla-
genase inhibitors; nevertheless, also cyclic structures are promising. 
 
Figure 4. Phosphinic peptide Z-Phe-ψ(PO2CH2)-Gly-Pro-Nle, a potent inhibitor of collagenase, re-
ported by Yiotakis et al. [69]. 
Phosphinic pseudodipeptides (PPDs) were described by Bhowmick, Fields et al. in 
2011 and 2012 [76,77]. All examined compounds were synthesised as building blocks in 
the Fmoc-containing form for further peptidomimetic development, with potential ap-
plication as MMPs inhibitors. In 2011, Fmoc-protected phosphinic analogues of Gly-Val 
and Gly-Leu were obtained, but supplemental inhibition assays were not performed. 
Additionally, in 2012, another PPD Fmoc-Gly-Ile was successfully developed. All deriva-
tives structures were based on common phosphonic peptides arrangement, reported in 
Figure 5. 
 
Figure 5. Common structural motif in phosphinopeptides [76]. 
Dive group achievements together with other scientists accomplishments in the 
field of phosphinic MMPs inhibitors, were summarized in the review by Yiotakis et al. in 
2004 [78]. Furthermore, it was reported by Gall et al. that the phosphinic moiety incorpo-
ration led to a good inhibition of stromelysin-3 (MMP-11) as well [79]. Moreover, Lauer-
Fields et al. proven a relevance of phosphinic peptides, a triple-helical transition state 
analogues, in MMP-2 and MMP-9 inhibition [80]. 
3.1.3. Unmodified Peptides 
Whilst hydroxamate and phosphonic modifications represent the main direction of 
collagenase inhibitors design about 30 years ago, after 2000 scientists begun to examine 
also unmodified sequences. Mostly, these peptides derive from proteolytic digestion 
fragments of other proteins from natural sources, mimicking biological substrates. Rec-
ognized by the collagenase, these peptides occupy its active site and decrease the catalyt-
ic ability. Another pathway comprises indirect activity when the aforesaid fragments are 
acting as signal peptides. Herein we will report sequences described within past 20 
years, possessing effective collagenases inhibitory properties. 
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Synthetic Peptides 
Oono et al. in 2002 investigated an influence of human neutrophil peptide-1 
(HNP-1) on MMP-1 and proα1-collagen type I expression [81]. However in this paper 
the HNP-1 sequence was not reported, while it can be found online as commercially 
available product: H-ACYCRIPACIAGERRYGTCIYQGRLWAFCC-OH (A) [82]. To ex-
plore the possibility of HNP-1 application in wound healing, these authors used one-
step reverse transcription polymerase chain reaction (RT-PCR) for semiquantitative 
analysis of mRNA of MMP-1 and proα1 collagen (type I and III). ELISA test was then 
applied in order to quantify the production of MMP-1 by fibroblasts treated and not 
treated with HNP-1. Their experiments suggested that HNP-1 upregulates collagen syn-
thesis and decrease collagenase activity. 
Field’s research group investigations have shown a significant role of peptides as 
inhibitors of MMPs, not only collagenases [83]. Among others, MMP-1 activity was no-
ticeably decreased in the presence of STX-S4-CT peptide (sequence C) [84]. Ki value was 
calculated for 4.5 μM. Regasepin1, a short peptide D, was found to be a good and selec-
tive inhibitor of collagenases—IC50 value for MMP-8 (collagenase-2) was 3 μM; in the 
case of MMP-1 and MMP-13 (collagenases-1 and -3) this value increased up to 100 μM 
[85]. Finally, TM8 peptide E inhibited all three collagenases well, with the Ki values of 
10, 28 and 12 nM for MMP-1, -8, and -13, respectively [86]. 
The crystallized complexes of catalytically inactive human collagenase-3 (MMP-13) 
with peptides were described by Stura et al. in 2013 [87]. Two different peptides (F and 
G) deriving from the cleaved prodomain proMMP-13 throughout activation were bound 
to the enzyme active site. N-terminal modifications within these sequences were variable 
and showed interactions in different parts of catalytic domain. Structural details of crys-
tals with relatively long peptide chains (up to 26 residues) can be found in Protein Data 
Bank library (codes 4FU4, 4FVL, and 4G0D). They refer to the complexes with the fol-
lowing peptides: G25GDEDDLSEEDLQFAERYLRSYYHPT50 (Figure 6, left), 
D30LSEEDLQFAERYLRSYYHPT50 (Figure 7), and 
G25GDEDDLSEEDLQFAERYLRSYYHPT50 with the full enzyme (Figure 6, right), respec-
tively. This study does not depict typical inhibitory properties of the mentioned se-
quences. Nevertheless, it can be a good starting point for new compounds development 
due to the structural properties and interactions found in crystals. 
  
Figure 6. Human collagenase 3 (MMP-13) in two complexes with peptide F (PDB codes: 4FU4, 
4G0D) [87]. The inhibitor molecules are presented as spheres. All figures of crystal structures were 
prepared in PyMOL [88]. 
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Figure 7. Human collagenase 3 (MMP-13) in the complex with peptide G (PDB code: 4FVL) [87]. 
The relevance of MMP-13 inhibitors as a useful tool for decreasing the collagen deg-
radation was confirmed by another study of Howes et al. [89]. Their investigations have 
shown that MMP-1 acts differently to MMP-13 and they recognize diverse collagen 
cleavage sites. Moreover, MMP-13 digest preferably collagen type II over types I and III, 
cleaving the α chains sequentially. To check the recognition sites in collagen, these au-
thors synthesised a library of overlapping homotrimeric peptides, including a 27 amino 
acids sequence from primary collagen and repeatable (GPP)5 fragments (located both on 
N- and C-terminus), providing a triple-helical conformation. Their studies revealed the 
highest affinity of MMP-13 to two sequences, so-called II-44 and II-8 (H and I, respec-
tively). The first peptide, II-44, was found to occur in a triple helix form in 80%; for II-4 
this value was 48% (at 37 °C). Calculated IC50 for both compounds shown a higher inhib-
itory potency for II-44 (IC50 = 8 μg/mL), while II-8 was a fourfold weaker inhibitor of 
MMP-13. Moreover, it was confirmed that the fragments essential for the recognition 
and responsible for a robust binding are GLXGQR, found twice in II-44 and not found in 
II-8. Therefore, it was possible to explain the slight difference observed between the ob-
tained results. 
Fields research group, previously mentioned, investigated MMP-13 triple-helical 
inhibitors J, K, and L, obtained using click chemistry [90]. These authors found that as-
sembling of three different chains into heterotrimeric helices provides adequate thermal 
stability and results in MMP-13 and MT1-MMP inhibition in the range 100–400 nM. 
What is more, the heterotrimeric analogues were selective between MT1-MMP and 
MMP-1, on the contrary to homotrimer-based structures, favouring MMP-13. 
Peptides from Natural Sources 
In 2011, Park et al. published an article delineating the isolation of a peptide inhibit-
ing MMP-1, derived from Dipturus chilensis skate skin protein [91]. The extracted protein 
was then digested by various enzymes, e.g., alcalase, α-chymotrypsin, trypsin, neutrase, 
papain, and pepsin. Obtained cocktails were then tested against collagenase-1, exhibit-
ing an inhibitory effect of pepsin hydrolysate. Bioactive peptide was purified, and mass 
spectrometry confirmed the molecular weight value 961 Da of purified product B Addi-
tionally, the IC50 value for the isolated peptide was 87.0 μM. 
3.1.4. Amino Acids and Peptide Derivatives 
Apart the above-mentioned categories of collagenases inhibitors, there are other 
uncategorizable molecules. One of them is MMP-13 inhibitor (MMP13i-A) described in 
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2011 by Quillard and co-authors [92]. It is a nonhydroxamate molecule, significantly de-
creasing MMP-13 activity (Figure 8). What is particularly interesting, among all tested 
MMPs (1, 2, 7, 8, 9, 12, 13, and 14) only MMP-13 was efficiently inhibited (IC50 = 33.5 
nM). Other metalloproteases shown no inhibition with IC50 value over 20000 nM. These 
observations suggested a certain selectivity and were applied during in vivo observa-
tions, including macrophage accumulation and MMP-13 activity monitoring. Mice treat-
ed for 10 weeks with MMP-13i-A, revealed reduced activity of MMP-13 without affect-
ing macrophage content, measured by molecular imaging. 
 
Figure 8. Chemical structure of MMP-13 inhibitor (MMP13i-A) [92]. 
A great example of cosmeceutically relevant compounds are Mycosporine-like 
Amino Acids (MAA) from marine sources [93]. According to the paper by Hartmann et 
al., three bioactive molecules were firstly isolated from the marine red algae (Porphyra 
sp., Palmaria palmata) and then chromatographically purified for further use. Inhibitory 
properties of shinorine, porphyra, and palythine were evaluated against Chlostridium his-
tolyticum collagenase. Obtained IC50 values are presented in the Table 3. To compare, 
two standard inhibitors phosphoramidon and 1,10-phenanthroline were considered ad-
ditionally in the assay. Furthermore, molecular docking study confirmed the competi-
tive mechanism of inhibition revealed by tested MAAs, with IC50 values between 100–
160 μM. 
Table 3. Mycosporine-like amino acids (MAA) from marine sources and two standard inhibitors, 
tested in the collagenase inhibition assay described by Hartmann et al. [93]. 
Name IC50 value 
Shinorine 104.0 ± 3.7 
Porphyra 105.9 ± 2.3 
Palythine 158.9 ± 3.2 
Phosphoramidone 1 18.8 ± 1.6 
1,10-phenanthroline 1 238.1 ± 3.4 
1 Standard inhibitor. 
In two papers from Fields, Roush et al., mentioned in the introduction of colla-
genases section, the authors evaluated inhibitory activity of various amino acids deriva-
tives against MMP-13 [61,62]. They reported the two potent and selective inhibitors, 10d 
and (S)-17b, occupying the MMP-13 binding site and surrounding the catalytically active 
Zn2+ ion, without its chelation. IC50s found for these two derivatives were calculated as 
3.4 nM and 2.7 nM, respectively. Then, Fuerst et al. identified the two compounds 2 and 
31, exhibiting improved microsomal half-life, kinetic solubility, and permeability coeffi-
cient. Both compounds were selective among three tested MMPs (IC50 values for com-
pound 2: 2.7 nM for MMP-13 and over 5000 nM for MMP-2, MMP-8; for compound 31: 
8.5 nM, over 5000 nM, and 832 nM for MMP-13, -2, and -8, respectively). 
A wide and detailed review describing inhibitors of MMPs in general, including 
collagenases, was published in 2020 by Raeeszadeh-Sarmazdeh et al. [94]. 
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3.2. Elastase 
In 1949 Baló and Banga published a communication in Nature, claiming that fresh 
pancreas extraction as well as dried pancreas powder “contains a specific enzyme, called 
‘elastase’” [95]. Thus, this was the first scientific statement describing this important en-
zyme, which was thereafter investigated by other researchers. Tsuji and co-workers de-
lineated the role of fibroblast elastase in wrinkle formation, providing also some indica-
tions in their inhibitors design [96]. These authors proven the importance of skin fibro-
blast elastase in elastic fibre degradation. At this point, it is worthy to underline that at 
least two elastase types are present in the skin, i.e., neutrophil and skin fibroblast elas-
tase. While the first is a serin protease, the latter belongs to the metalloprotease family 
[97]. Because both of them have the ability to degrade fibrillar collagen, we will high-
light the interesting inhibitors of each one. 
In a paper by Imokawa group, the authors evidenced an undoubted difference be-
tween these elastases [96]. Comparing different enzyme inhibitors, inhibiting profiles for 
both neutrophil and fibroblast elastase were created. Among PMSF (phenylmethyl sul-
fonylfluoride), elastatinal, leupeptin, pepstatin A, EDTA, 1,10-phenantrolin, and phos-
phoramidon, the last one (already listed in Table 2) together with EDTA and, 
1,10-phenantrolin (all known as metalloprotease inhibitor), significantly decreased the 
fibroblast elastase activity. On the other hand, neutrophil elastase remained active in 
these conditions, inhibited only by PMSF and elastatinal (typical serine protease inhibi-
tors). Thus, the dissimilarity between the mechanisms of action of the two elastases was 
proven and explained. Additionally, the work by Azmi et al. showed a relevant inhibito-
ry activity of elastase, tyrosinase, and MMP-1 by worm extracts, indicating its potential 
application in the cosmeceutical field [98]. However, due to the biological extract incor-
poration instead of purified compounds, precise inhibitory differences among three 
evaluated enzymes cannot be clearly distinguished. 
For more detailed papers about biological activity and functions of human neutro-
phil elastase (HNE), together with examples of diverse inhibitors, we indicate a set of 
review papers by Ohbayashi et al., Kelly et al., Groutas et al., and a recently released one 
by Ahmad et al. [99–102]. 
3.2.1. Chloromethyl Ketones 
One of the very first papers describing the inhibition of porcine pancreas elastase 
(PPE), human leukocyte elastase (HLE), and cathepsin G (CatG) was published in 1977 
by Powers et al. [103]. The cleavage pattern of various peptides by PPE was examined, 
thus determining substrate structural preferences. Afterwards, a few new chloromethyl 
ketones Ac-Ala-Ala-Pro-AACH2Cl (where AA = Ile, Val, Thr) were synthesised. PPE was 
inhibited more rapidly by the peptide bearing Ile, while the Thr variant did not show 
significant inhibition. On the other hand, HLE was inhibited more efficiently by se-
quences including Ile and Val. MeO-Suc-Ala-Ala-Pro-ValCH2Cl, soluble in water, was 
established as a very-good inhibitor of HLE; Z-GIy-Leu-PheCH2Cl was effective against 
cathepsin G, but not leukocyte elastase. 
In 1989, Navia and co-workers presented a work in the field of peptide chlorome-
thyl ketones as HNE inhibitors [104]. They have noticed some side effects of peptides 
evaluated by Powers et al. in humans, and therefore designed new molecules with di-
minished toxicity. Crystal structure of methoxysuccinyl-Ala-Ala-Pro-Ala chloromethyl 
ketone (MSACK) is presented in Figure 9. It was proven that MSACK is able to form the 
cross-linkage between the His-57 and Ser-195 residues, responsible for the catalytic ac-
tivity. 
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Figure 9. Structure of human neutrophil elastase in complex with MSACK (PDB code: 1HNE) 
[104]. The inhibitor molecule is presented as spheres. 
In vivo experiments on rats were reported in the paper by Cowan et al. [105]. Ani-
mals with advanced pulmonary vascular disease were then treated with peptidyl tri-
fluoromethylketone serine elastase inhibitors, so-called ZD0892 and M249314. It was 
demonstrated that untreated rats have shown 900% loss of cellular matrix after 21 days, 
with further increase of 800% within next week. After M249314 administration, elastase 
inhibitory activity was noticeable over the first 6 hours, and then decreased but re-
mained evident until the second dose. What is more, the mortality of sick and untreated 
rats has begun after 23 days, while after 28 days only one rat from each group (ZD0892 
and M249314-treated for 1 week) was died. Summarizing, the survival of 
M249314-treated rats was 86%, whereas all untreated rats had died by 30 days of the tri-
al. 
3.2.2. Cyclic Depsipeptides  
Advantages of cyclic structures were already mentioned previously in the para-
graph related to collagenases. In 2001 and 2003, Matern et al. described the inhibition of 
PPE by scyptolin A and B, together with the crystal structure of scyptolin A bound to 
this enzyme [106,107]. Two cyclic depsipeptides (peptides with one or more amides re-
placed by the ester groups) were isolated from cyanobacterium Scytonema hofmanni 
PCC7110, namely scyptolin A and B. Both molecules were selective inhibitors of PPE, 
exhibiting IC50 values of approximately 3 mg/mL. The crystal structure has shown the 
rigid ring of scyptolin A occupying the elastase active site, thus preventing a hydrolytic 
attack and decreasing the enzyme activity (Figure 10). Due to the similarity of PPE and 
human elastase, the structures of scyptolin A and B appear as valuable starting points 
for further investigations in the field of human elastase inhibitors. 
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Figure 10. Binding structure of elastase inhibitor Scyptolin A (PDB code: 1OKX) [107]. The inhibi-
tor molecules are presented as spheres. 
Another interesting example of cyclopeptides from natural sources, relevant as elas-
tase inhibitors, were presented a recent paper by Keller et al. [108]. These authors de-
scribed three new cyclic peptides, so-called tutuilamides A–C, structurally defined by 
various techniques such as NMR and chemical derivatization. Particularly, 3-amino-6-
hydroxy-2-piperidone and 2-amino-2-butenoic acid, and a novel vinyl chloride residue, 
were found in these sequences. IC50 values obtained during the PPE inhibition assay 
were 1.18, 2.05 and 4.93 nM for tutuilamide A, B, and C, respectively. Moreover, trypsin 
inhibition was not found in the presence of the discussed cyclopeptides (IC50>20 000). 
X-ray crystallography revealed the formation of hydrogen bond between the amino acid 
backbone of tutuilamide A and the enzyme binding pocket, thus stabilizing the complex 
end explaining the inhibitory activity. 
3.2.3. Unmodified Peptides 
Structurally unmodified sequences can be found in the literature, too. In 1995, Toth 
et al. published the results of in vitro and in vivo studies, concerning lipophilic peptide 
inhibitors of human neutrophil elastase [109]. Four lipopeptides, namely 1b–e, shown 
relevant HNE inhibition. Obtained IC50 values were 2.9 × 10−9, 2.8 × 10−10, 1.8 × 10−l0, and 
4.1 × 10−l0 mmol × mL−1, for 1b, 1c, 1d, and 1e, respectively. It was found that the inhibi-
tion was increasing while the lipophilicity of sequences was higher: moreover, carbox-
ylic acid esterification in analogue 1e led to decreased inhibitory effect. All sequences 
were based on X-AAPV-Y fragment, with proper N- and C-terminal modifications (X 
and Y, respectively). All evaluated sequences are reported in the Table 4. In vivo exper-
iments on rabbit skin proved the protection of elastic fibre against elastolysis, exhibited 
by the lipopeptide 1d (M) administered intradermally.  
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Table 4. Lipopeptides reported in Toth et al. [109] All structures are based on X-AAPV-Y frag-







In 2000, Hilpert et al. designed and conducted a very broad investigation in order to 
identify and finally modify a sequence for efficient PPE inhibition [110]. Shorter chains 
were designed on the basis of OMTKY3 (third domain of turkey ovomucoid inhibitor), 
exhibiting the Ki value of 5.5 × 10−12 M. Synthesis of peptides together with their cyclisa-
tion were performed on cellulose membranes, and were followed by the binding affinity 
measurements carried out on the membrane, too. The significance of each amino acid 
was determined by the exchange of every residue with each one of the other 19 coded 
amino acids. Thereby, over 700 different sequences were evaluated in binding to PPE, 
and 320 of them were then measured in the inhibition assay in microtiter plates with 
punched out peptide spots. Interestingly, cyclization did not provide any beneficial in-
teractions in the active cleft and did not provoke an extended inhibition. Among all test-
ed sequences, the shortest one exhibiting the 84% decrease of PPE activity, was peptide 
N. Ki values were of 6.7 × 10−7 M, 1.1 × 10−4 M, and 1.3 × 10−4 M for PPE, HLE, and BPC 
(bovine pancreas α-chymotrypsin), respectively. Furthermore, the described experiment 
including N sequence has been continued and broaden into the hybrid miniprotein de-
sign, inhibiting PPE likewise [111]. 
Another study on synthetic peptides as HNE inhibitors was performed by Vascon-
celos et al. in 2011 [112]. Inhibitory effect on HNE and PPE of two sequences were com-
pared to commercially available elastatinal. These sequences were based on Bowman–
Birk protein-derived peptides able to inhibit HNE, summarized by McBride et al. [113]. 
Peptides O and P resulted to act as competitive inhibitors of HNE, with higher efficacy 
found for the sequence of peptide P. Probably, the increased hydrophobicity conferred 
by the (GA)7 tail provided relevant interactions with the enzyme, thus confirming the re-
sults reported in the previously mentioned work by Toth et al. [109]. Obtained IC50 val-
ues were at micromolar level (for the peptide 2: 8.1 and 6.3 μM; for the peptide P: 7.0 
and 0.4 μM in the case of PPE and HNE, respectively). 
One more example of non-modified peptide sequence, applicable as elastase inhibi-
tor, was presented in the paper by Wan et al. in 2013 [114]. Authors identified the first 
Kunitz-type serine protease inhibitor, namely AvKTI (R), found in Araneus ventricosus 
spider. The amino acid sequence was deduced from AvKTI cDNA from GenBank and 
established as KDRCLLPKVTGPCKASLTRYYYDKDTKACVEFI-
YGGCRGNRNNFKQKDECEKACTDH (57 residues). Its activity against plasmin and 
elastase was proven, with Ki values of 4.89 nM and 169.07 nM, respectively, whereas IC50 
values were calculated as 10.07 and 446.93 nM, respectively. 
3.2.4. Peptide Derivatives and Cyclic Compounds 
In this paragraph we would like to pay particular attention to the peptide and pep-
tide-like sequences without functional groups belonging to the wider category described 
above, and exhibiting a relevant inhibitory activity of elastase. Therefore, macrocyclic 
compounds, together with unnatural amino acid-containing sequences will be described 
further. Exceptionally, we will also mention a few non-peptide molecules, in order to 
provide valuable indications for further design of new compounds. 
In 2000, Nakanishi and co-workers determined the crystal structure of PPE in the 
complex with FR901277 inhibitor (S), a natural compound extracted from the culture fil-
trate of Streptomyces resistomicificus (Figures 11 and 12) [115]. Previous examination of 
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this compound against HLE and PPE, resulted with the IC50 value of 18 and 26 μM, re-
spectively [116]. FR901277 consists of 7 amino acids, among which 4 are natural amino 
acids [L-Orn(1), L-Thr(2), L-Phe(5), and L-Val(7)] and 3 are unusual [dehydroxyThr(3), 
AA(4), and AA(6)], with the bridge between L-Thr(2) and L-Val(7). The crystal structure 
of PPE with FR901277 have shown the occupation of PPE binding subsites by inhibitor 
hydrophobic residues, with additional van der Waals contacts. 
 
Figure 11. Crystal structure of porcine pancreatic elastase in complex with S (PDB code: 1QR3) 
[115]. The inhibitor molecule is presented as spheres. 
 
Figure 12. Crystal structure of porcine pancreatic elastase in complex with S (PDB code: 1QR3) 
[115]. The proximity of His-57 and Ser-195 residues (green) and the inhibitor molecule (pink) is 
visible. 
The relevance of elastase inhibition in cosmeceutical application has been already 
noticed in early 2000s by Tsukahara et al. [117]. These authors reported a significant role 
of elastase in the damage of dermal elastic fibres, leading to wrinkle formation. N-
phenetylphosphonyl-leucyl-tryptophane (NPLT), an elastase inhibitor, was applied top-
ically 5 times a week on rat skin, leading to diminished wrinkle formation and main-
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tained skin elasticity. 0.1 ± 10.0 mM concentrations were tested, revealing the peak of ef-
ficacy at 1.0 mM concentration. 
Novel, low-molecular HNE inhibitors were described by Schepetkin et al. in 2007, 
setting a milestone in heterocyclic elastase inhibitors field [118]. Structures based on 
N-benzoylpyrazoles were eventually modified and optimized, leading to a library of po-
tent compounds (for a general structure of N-benzoylpyrazoles, please see the Figure 13) 
and 17 molecules were then chosen for further experiments and SAR (structure-active 
relationship) analysis, revealing Ki values between 6-300 nM. Molecular docking studies 
were performed in order to explain the differences in potency among the most active 
and inactive compounds. It has been noticed that the carbonyl group of the inhibitor was 
located in the NE binding site, thus interacting with the catalytic triad. On the other 
hand, inactive analogues were either sterically hindered, or showed unpreferable orien-
tation, hence excluding the presence of relevant interactions. 
 
Figure 13. General chemical structure of N-benzoylpyrazoles. 
Starting from 2011, Giovannoni group was working on N-benzoylindazole deriva-
tives acting as HNE inhibitors, progressing the work of above-mentioned Quinn’s inves-
tigations [119,120]. Among all tested compounds, so-called 8a and 8b showed the most 
potent, competitive and pseudo-irreversible inhibition, with IC50 values of ≈0.089 and 
≈0.13 μM, respectively. Accordingly, also in this study molecular modeling have high-
lighted the importance of the carbonyl group in the N-benzoylindazole derivatives struc-
tures, due to the favourable interactions with -OH from Ser195 in the active cleft. Going 
forward, other analogues were developed to increase the inhibition efficacy and overall 
stability. Two more compounds, 5b and 20f, resulted with the inhibition level of IC50 ≈ 7 
and 10 nM, respectively (Figure 14). 
 
Figure 14. N-benzoylindazole derivatives presented in the papers by Crocetti et al. 
[119,120]. 
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3.3. Cathepsins 
Among a variety of cathepsins, the most relevant classes for cosmeceutical purposes 
are cathepsins K, L, and S (CatK, CatL, and CatS, respectively). These endopeptidases 
belongs to the cysteine cathepsins family and regulate several biological functions, such 
as inflammatory and proteolytic processes, or ECM remodeling [121]. Due to their role 
in fibrillar collagen degradation, a few examples of cathepsins inhibitors will be reported 
here. 
Brömme and Lecaille summarized the features of the ideal CatK inhibitor, pointing 
to the importance of low molecular mass, minimal peptide character, reversibility and 
selectivity [122]. Aguda et al. evidenced that CatK is capable of fibrillar collagen degra-
dation, underlining the participance of collagen-bound glycosaminoglycans in this pro-
cess [123]. Additionally, a role of CatL in type I collagen degrading pathway was proved 
by Parks et al. [32]. It was found that CatL requires the presence of CatK to degrade ef-
fectively tendon ECM. 
3.3.1. Peptide Aldehydes 
Peptidyl aldehydes as cathepsins inhibitors are known at least since 1969, when 
leupeptin (Ac-Leu-Leu-Arg-CHO, T) and antipain (N-[Nα-carbonyl-Arg-Val-Arg-al]-
Phe, U) were described for the first time [124,125]. Then, in 1990 Sasaki et al. synthesised 
eight different di- and tripeptide aldehydes [126]. Each analogue contained L-leucine fol-
lowed by an aldehyde located at the C-terminus (on L-norleucine, L-methionine, or L-
phenylalanine). Performed enzymatic tests shown the inhibition of cathepsin B and L, 
with a particular efficacy against the second one. V inhibited CatL with Ki = 0.5 nM; X 
inhibited CatB with Ki = l00 nM. 
Building on the efficacy of the above-mentioned analogues, Votta et al. in 1997 pub-
lished a study dealing with other peptide-aldehyde inhibitors [127]. Two classes of com-
pounds were distinguished, namely time-dependent and time-independent inhibitors. 
Cbz-Leu-Leu-Leu-CHO (Y) was selected to be the most potent one, classified into the 
time-independent group. The values of Ki and IC50 were 1.4 nM and 0.02 μM, respective-
ly. Furthermore, Y reduced extensive bone loss provoked by CatK. 
Other than CatK and CatL, also CatS became known to be inhibited by peptidic al-
dehydes. In 2000, Walker et al., from already mentioned Brömme group, published an 
evaluation of dipeptide α-keto-β-aldehydes (glyoxals) as new inhibitors of cathepsin S 
[128]. Through the solid-phase peptide synthesis (SPPS), a spectrum of dipeptide ana-
logues was obtained and tested against cathepsin S. One of them, Z, exhibited good se-
lectivity (Ki = 0.185 nM for CatS and 76 nM for CatB) (the structure can be found in the 
Figure 15). 
 
Figure 15. Cbz-Phe-Leu-COCHO (Z), one of the most relevant peptide aldehydes evaluated in the 
work by Walker et al., exhibiting CatS inhibition [128]. 
3.3.2. Peptidic Nitriles 
Balicatib (AAE581), a basic peptide nitrile, has been developed by Novartis and was 
found to be a potent and selective inhibitor of human CatK (IC50 = 0.0014 μM, compared 
to 2.9–28 μM for other cathepsins) [129]. Administered orally, was applied in osteoporo-
sis treatment [130]. Another example is odanacatib (MK-0822) together with MK-1256 
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analogue [131,132]. Odanacatib inhibits CatK, B, L, and S with IC50 values of 0.2 nM, 
1034 nM, 2995 nM, and 60 nM, respectively. CatK inhibition by MK-1256 was effective 
and selective among other cathepsins (IC50 = 0.62 nM, >1100-fold less potent against CatL 
and CatS i.a.). Incorporation of balicatib and odanacatib scaffolds was then evaluated by 
Burtoloso et al. in 2017 [133]. These authors developed new compounds with an-
ti-trypanosomal activity, relevant for the discovery of further anti-chagasic agents. All 
depicted structures, and the inhibitory values are summarized in the Table 5. 
Table 5. Structures and IC50 values obtained for peptidic nitriles, selective inhibitors of cathepsin K. 
Compound Structure IC50 Value for CatK  Reference 
Balicatib (AAE581) 
 
0.0014 μM [129] 
Odanacatib (MK 0822) 
 
0.2 nM [131] 
MK-1256 
 
0.62 nM [132] 
For a broad review dealing with nitrile-based peptide inhibitors of cathepsins, sup-
ported by the knowledge of this inhibitory mechanism, we highlight the paper by Frizler 
et al. published in 2010 [134]. 
3.3.3. Peptide Ketoheterocycles 
(Keto)heterocyclic modifications of peptides were assessed in cathepsins inhibition 
at the beginning of 2000s. McGrath and colleagues synthesised a set of peptide 
α-ketoheterocyclic inhibitors, occupying the substrate recognition cleft of targeted cyste-
ine protease CatK [135]. Molecular modeling supported by the crystallographic data re-
vealed the reversible covalent bonding with Cys25 nucleophile. One of the most potent 
examples is the compound 4, presented in the Table 6. Ki values calculated for 4 and 
CatK, B, L, and S were of 0.0029 nM, 0.64 nM, 0.02 nM, and 0.0066 nM, respectively. 
Quibell group in 2004 and 2005 reported the synthesis and evaluation of cis-
hexahydropyrrolo[3,2-b]pyrrol-3-one, and bicyclic peptidomimetic tetrahydrofuro[3,2-
b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridine-3-one derivatives as cysteinyl proteas-
es inhibitors [136,137]. In their first paper, 5,5-bicyclic ketone-containing scaffold was 
depicted, underlining the valuable chiral stability. Kinetic analysis shown a significantly 
lower association with CatK of 6,5-analogues, and subsequently lower potency. Among 
all synthesised compounds, 10 was found to be the most effective and exhibited sub-
micromolar potency in the cell-based assay (Table 6). This idea was further pursued and 
in 2005 another analogue, i.e., compound 22, was described as an even more potent CatK 
inhibitor than those previously reported (Table 6). 
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Table 6. Structures and Ki values in nM obtained for heterocyclic peptidomimetics, synthesised and evaluated against 
various cathepsins. Results for CatK, L, and S are evidenced. 
Compound Structure 
Cathepsin K 




Ki [nM] Reference 
4 
 
0.0029 0.02 0.0066 [135] 
10 
 
87.4 ₊/₋ 0.8 >25 000 >41 000 [136] 
22 
 
10.1 ₊/₋ 6.7 >3500 >4500 [137] 
Moreover, a summary of patents revealed in the field of cathepsin K inhibitors was 
published by Wijkmans and Gossen in 2011 [138]. 
4. Conclusions and Future Prospect 
Collagen represents approximately one-third of all human body proteins, being the 
most abundant protein-like body component. The essential role played by collagen has 
an influence on many physiological, as well as pathological states. For example, dys-
functional collagen turnover and its increased degradation lead to wound healing dis-
ruption, skin photoaging, and loss of skin firmness and elasticity. Therefore, inhibitors of 
enzymes leading to the degradation of fibrillar collagen were in the spotlight for years, 
and still are the focus of many research projects. Healthy and younger-looking skin be-
comes increasingly significant targets, as they contribute to the wellness of each individ-
ual, as clearly shown by the critical growth of the skin-care products market observed 
recently. In this review, we describe a group of inhibitors of enzymes degrading fibrillar 
collagen, paying attention to peptides and peptidomimetics (Scheme 3 and Table 7). Ad-
ditionally, a few valuable non-peptide molecules were mentioned, thereby providing a 
platform for further investigations and design of new active compounds. Prospectively, 
these peptides and peptidomimetics, together with their analogues, can be applicable as 
active ingredients in the cosmeceutical field. 
 
Scheme 3. Scheme presenting all classes of inhibitors discussed in this review. 
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Table 7. Summary of unmodified peptide sequences exhibiting collagenases and elastases inhibition, together with pep-














B NLDVLEVF [91] 
C CSCSDMTDKECLYFCMSEMS [84] 
D PRCBCGE [85] 











  1 (GPO)5GPQ{Gψ(PO2H-CH2)I}AGQRGIR(GPO)5GPra 
                              (GPO)6GPQGLAGQRGIR(GPO)5G-Lys-Lys-
NH2 
        (GPO)6GPQGLAGQRGIR(GPO)5G-HN 
 
                       (GPO)5GPQGLAGQRGIR(GPO)5G-Pra 
   (GPO)6GPQ{Gψ(PO2H-CH2)I}AGQRGIR(GPO)5G-Lys-Lys-NH2 
 (GPO)5GPQGLAGQRGIR(GPO)5GPra 
 















N PMTLEYR [110] 
O MGWCTASVPPQCYG 


















Y Cbz-LLL-CHO [127] 
Z Cbz-FL-COCHO [128] 
1    – indicates the sites of click ligation; O – Hyp. 2 AA1, AA2—non-abbreviated, unnatural amino acids. For cyclic and detailed 
structures, please see the references. 
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